A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Launched by MERCK SHARP & DOHME LLC · Nov 8, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with symptomatic knee osteoarthritis for at least 6 months based on clinical and radiographic criteria
• • Patients should be in general good health and must have a certain level of knee pain or be taking pain medicines on most days
• • Specific radiographic (X-ray) and MRI features must also be satisfied
• Exclusion Criteria:
• • Non-osteoarthritic causes of knee pain
• • Ineligibility to undergo MRI of the knee due to patient tolerability or safety reasons
• • Previous septic arthritis, tibial osteotomy or knee replacement in both knees
• • Acute injury of knee ligaments or meniscus in past 2 years
• • Knee arthroscopy in past 12 months
• • Anticipated arthroscopy or surgery in next 18 months
• • Use of intra-articular injections of hyaluronan (e.g. Hyalgan (TM), Synvisc (TM), Orthovisc (TM)) in past 6 months, or injections of glucocorticoids (e.g. Kenalog (TM), Aristospan (TM), Depo-Medrol (TM)) in past 3 months or anticipated knee injections during the study
• • Glucosamine or chondroitin sulfate are allowable if they are at a stable dose for past 3 months and will continue at that dose during the study
• • Other exclusion criteria apply-Please ask the study doctor for details